Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Genscript Biotech's Revenue for the
six
months ended in Dec. 2025 was $440.8 Mil. Genscript Biotech's average Accounts Receivable for the
six
months ended in Dec. 2025 was $128.4 Mil.
Hence, Genscript Biotech's Receivables Turnover for the
six
months ended in Dec. 2025 was 3.43.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Genscript Biotech Receivables Turnover Related Terms
Genscript Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNNSF vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Genscript Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a Receivables Turnover of 3.43 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genscript Biotech and its competitors. According to the industry distribution chart, Genscript Biotech ranks #260 out of 841 companies in the Biotechnology industry, placing it in the top 30.9%.
Is Genscript Biotech's Receivables Turnover too high?
Genscript Biotech's current Receivables Turnover is 3.43. The Biotechnology industry median Receivables Turnover is 5.29. Genscript Biotech's value of 3.43 is 35.2% below this industry median. Based on the distribution chart, Genscript Biotech ranks #260 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #260 out of 841 companies for Receivables Turnover. This puts Genscript Biotech in the upper half of its industry. The industry median Receivables Turnover is 5.29. Genscript Biotech's value of 3.43 is 35.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Receivables Turnover of 3.43 is 35.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Receivables Turnover is 3.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.31, compared to a current price of $2.00 — trading 13.4% below its estimated fair value. The current Receivables Turnover is 3.43 and 35.2% below the Biotechnology industry median of 5.29. Genscript Biotech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Receivables Turnover is 3.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $2.00 is trading 13.4% below its estimated GF Value™ of $2.31.
GuruFocus considers Genscript Biotech to be Modestly Undervalued.
Key valuation signals for GNNSF:
Receivables Turnover: 3.43
GF Value™: $2.31 vs. price of $2.00 (13.4% below fair value)
Industry Position: 35.2% below the Biotechnology median (#260 of 841)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
72GF Score
Get the complete analysis for GNNSF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
